SRP-4045
4045-101
Phase 3 small_molecule completed
Quick answer
SRP-4045 for Duchenne Muscular Dystrophy is a Phase 3 program (small_molecule) at Sarepta Therapeutics with 2 ClinicalTrials.gov record(s).
Program details
- Company
- Sarepta Therapeutics
- Indication
- Duchenne Muscular Dystrophy
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed